Article

HIV- positive anal cancer: an update for the clinician.

Department of Radiation Oncology, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Journal of gastrointestinal oncology 09/2010; 1(1):34-44. DOI: 10.3978/j.issn.2078-6891.2010.005
Source: PubMed

ABSTRACT Anal cancer used to be a rare cancer traditionally associated with elderly women. There are approximately 5260 cases per year in the U.S. (1). The onslaught of the Human Immunodeficiency Virus (HIV) virus has led to a change in anal cancer demographics. Anal cancer is on the rise in the U.S and the number of anal cases documented has quadrupled in the past 20 yrs correlating with the rise of the HIV epidemic. The incidence of anal cancer is 40 to 80 fold higher in the HIV positive (HIV+) population when compared to the general population (2). With the advent of highly active antiretroviral therapy (HAART), HIV+ patients are living longer as less are progressing to AIDS. As a consequence non AIDS defining cancers such as anal cancer are on the rise. Factors implicated in the etiology of anal cancer in HIV+ patients include (Human papillomavirus) HPV virus status, sexual habits, and a history of smoking. HPV 16 and receptive anal intercourse (RAI) increase the risk of anal cancer by 33% over the general population. In the general population, the rate of anal cancer is approximately 0.9 cases per 100,000. In patients with a history of RAI, the rate approaches 35 cases per 100,000 which is equivalent to the prevalence of cervical cancer (3). Smokers are eight times more likely to develop anal cancer. There has been much discussion about tailoring treatment decisions in HIV+ patients with anal cancer. This review focuses on squamous cell carcinomas of the anal canal which comprise 80 to 90% of all anal cancers diagnosed and highlight key issues in the management of HIV+ anal cancer patients including recent clinical trials.

1 Follower
 · 
106 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To appraise the role of volumetric modulated arc (RapidArc, RA) in the treatment of anal canal carcinoma (ACC). A retrospective analysis has been conducted on 36 patients treated with RA since 2009 comparing outcome against a group of 28 patients treated with conformal therapy (CRT). RA treatments were prescribed with SIB technique with 59.4 Gy to the primary tumor and nodes and 49.5 Gy to the elective nodes. CRT was sequentially delivered with 45 Gy to the pelvic target and a boost of 14.4 Gy to the primary tumor. Median age of patients was 65 yrs for RA (59 yrs for CRT); 90% had Stage II-III (93% in the CRT group). No statistically significant differences were observed concerning survival or control. 5 yrs disease specific survival was 85.7% and 81.2%, loco-regional control was of 78.1% and 82.1% for RA and CRT respectively. RA treatments lead to lower incidence of higher grade of toxicity events (all retrospectively retrieved from charts as worse events). Grade 2-3 toxicity, compared to CRT, reduced from 89% to 68% for GI, from 39% to 33% for GU and from 82% to 75% for the skin. Late toxicity was as follows: 5/36 (14%) and 3/36 (8%) patients had G1 or G2 GI toxicity in the RA group (1/28 (4%) and 4/28 (14%) in the CRT group). GU late toxicity was observed only in 4/28 (14%) patients of the CRT group: 3/28 (11%) had G2 and 1/28 (4%) had G1. RA treatments of ACC patients proved to be equally effective than CRT but it was associated to a reduction of toxicity.
    BMC Cancer 11/2014; 14(1):833. DOI:10.1186/1471-2407-14-833 · 3.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anal cancer is an uncommon gastrointestinal tract malignancy rising in incidence annually for the past 5 years. Though subdivided into perianal and anal canal cancers, squamous cell carcinoma (SCCA) is the major variant. High risk HPV are associated with most SCCA. It is also evident that SCCA of the anal canal is highly prevalent in HIV+ patients. Over the past few decades, few studies have been conducted on anal cancers to describe the progress of basic and clinical research regarding SCCA of the anal canal. In this article, the discussion has been focused on the recent clinical developments and optimal recommendations for the management of SCCA of the anal canal, including anal cancer screening based on currently available data.
    Expert Review of Anticancer Therapy 07/2014; DOI:10.1586/14737140.2014.919861 · 3.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Smoking tobacco has many adverse health consequences. Patients with HIV infection smoke at very high rates, and many of the co-morbidities associated with smoking in the general population are more prevalent in this population. It is likely that a combination of higher smoking rates along with an altered response to cigarette smoke throughout the body in those with HIV infection leads to increased rates of the known conditions related to smoking. Several AIDS-defining conditions associated with smoking have been reviewed elsewhere. This review aims to summarize the data on non-AIDS related health consequences of smoking in the HIV-infected population and explore evidence for the potential compounding effects on chronic systemic inflammation due to HIV infection and smoking.
    Clinical Infectious Diseases 04/2013; 57(2). DOI:10.1093/cid/cit207 · 9.42 Impact Factor

Preview

Download
0 Downloads
Available from